- Home
- NVT vs ILMN Comparison
NVT vs ILMN Comparison
Compare NVT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | ILMN |
|---|---|---|
| Founded | 1903 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 19.4B |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NVT | ILMN |
|---|---|---|
| Price | $130.50 | $120.96 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 17 |
| Target Price | ★ $126.60 | $124.24 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | 118.78 | ★ 170.87 |
| EPS | 4.31 | ★ 5.45 |
| Revenue | $3,893,100,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $19.29 | $6.52 |
| Revenue Next Year | $11.97 | $5.60 |
| P/E Ratio | $29.89 | ★ $22.71 |
| Revenue Growth | ★ 29.51 | N/A |
| 52 Week Low | $47.86 | $69.88 |
| 52 Week High | $130.43 | $155.53 |
Technical Indicators
Market Signals| Indicator | NVT | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 43.87 |
| Support Level | $94.87 | $115.45 |
| Resistance Level | N/A | $128.96 |
| Average True Range (ATR) | 4.81 | 5.01 |
| MACD | 1.07 | 0.14 |
| Stochastic Oscillator | 93.45 | 26.32 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.